Download PDF
Fortschr Neurol Psychiatr 2013; 81(2): 88-94
DOI: 10.1055/s-0032-1330508
Originalarbeit
© Georg Thieme Verlag KG Stuttgart · New York

Liquid Ecstasy in der Allgemeinpsychiatrie: eine Fallserie

Liquid Ecstasy in General Psychiatry: A Case Series
R. W. Freudenmann
,
E. Baumgarten
,
A. E. Hawlik
,
M. Gahr
,
C. J. Schönfeldt-Lecuona
Further Information

Publication History

Publication Date:
14 February 2013 (online)

    Permissions and Reprints

Zusammenfassung

Hintergrund: In der Intensivmedizin ist Liquid Ecstasy (LE), der Straßenname für GHB, GBL oder 1,4-B, mittlerweile gut als Ursache schwerer Intoxikationen und Entzugssyndrome bekannt, weniger dagegen in der Allgemeinpsychiatrie. Daher war es unser Ziel, Informationen über die Bedeutung von LE in der Allgemeinpsychiatrie, typische User und häufige klinische Probleme bei ihrer Versorgung zu sammeln.

Methoden: Es wurden alle an der Ulmer Universitätspsychiatrie von 1998 – 2011 behandelten Fälle mit anamnestischem LE-Gebrauch retrospektiv identifiziert und ausgewertet.

Ergebnisse: Im Suchzeitraum von 14 Jahren wurden 19 Patienten mit LE-Konsum gefunden, der erste Fall aus dem Jahr 2005. Vornehmlich wurde ein GBL-Konsum angegeben (63 %), seltener GHB, 1,4-B nie. Es handelte es sich überwiegend um junge Männer (medianes Alter 25 J., 79 % Männer) mit polytoxikomanem Hintergrund. Zehn Patienten hatten LE nur früher eingenommen, 9 nahmen es zum Zeitpunkt der Vorstellung. Von diesen musste jeder dritte Patient vorübergehend auf der Internistischen Intermediate Care-Station versorgt werden, meist wegen plötzlicher schwerer Entzugssyndrome. Sonst war die Entgiftung in der Psychiatrie mit Benzodiazepinen in teils hoher Dosis möglich. Bei 3 Patienten bestand eine Abhängigkeit von GBL.

Schlussfolgerungen: Seit einigen Jahren werden LE-User auch in der Allgemeinpsychiatrie in begrenzter Zahl vorstellig. Das Problem ist weniger die Zahl der Fälle als die Schwere der Entzugssyndrome, die eine enge Kooperation mit der Intensivmedizin nötig macht. Bei plötzlichen unklaren Bewusstlosigkeiten und rasch entstehenden Entzugsdelirien sollte an den Gebrauch bzw. Entzug von LE gedacht werden. Viele der klinischen Probleme resultieren auch aus der Nichtnachweisbarkeit von LE im Routinedrogenscreening. Unserer Erfahrung nach lassen sich LE-Entzugssyndrome mit Benzodiazepinen gut kupieren.

Abstract

Background: In emergency medicine and anesthaesiology liquid ecstasy (LE), the street name for GHB, GBL or 1,4-B, has become infamous for causing severe intoxications and withdrawal. In general psychiatry, however, it is little known. Therefore, we set out to gather data about the role of LE in general psychiatry, typical users and common clinical problems associated with the use of LE.

Methods: We retrospectively identified and studied all patients with a reported the use of LE seen at the Department of Psychiatry, University of Ulm, Germany, between 1998 and 2011.

Results: In 14 years, 19 users of LE were identified, the first dating from 2005. The majority reported a use of GBL (63 %), GHB was less common, and 1,4-B was not reported. Patients were predominantly young men (median age 25 years, 79 % men) with a history of multiple substance abuse. Ten patients had only a former use of LE, the other nine patients used it at the time of presentation. Of these, every third patient had to be transiently treated in an intermediate care unit, usually because of very severe and sudden withdrawal symptoms. Otherwise, detoxification was possible in psychiatry, but often required high doses of benzodiazepines. Three patients met the criteria for dependence from GBL.

Conclusions: In recent years, a small number of users of LE is seen also in general psychiatry, The problem is rather the severity of withdrawal than the number of cases. Close cooperation with intermediate care units is needed. In any case of coma of unknown origin or delirium with sudden onset LE use or withdrawal has to be taken into consideration, respectively. Many clinical problems result from the fact that LE cannot be detected in routine drug screenings. According to our experience, withdrawal from LE can be controlled with benzodiazepines.

Schlüsselwörter

Liquid Ecstasy - Lösungsmittel - Gamma-Hydroxybutyrat (GHB) - Gamma-Butyrolacton (GBL) - Allgemeinpsychiatrie

Key words

liquid ecstasy - solvents - gamma-hydroxybutyric acid (GHB) - gamma-butyrolactone (GBLK) - general psychiatry
 

  • Literatur

  • 1 Degenhardt L, Darke S, Dillon P. The prevalence and correlates of gamma-hydroxybutyrate (GHB) overdose among Australian users. Addiction 2003; 98: 199-204
    CrossrefPubMedGoogle Scholar
  • 2 Andresen H, Stimpfl T, Sprys N et al. Liquid Ecstasy – ein relevantes Drogenproblem. Dtsch Arztebl 2008; 105: 599-603
    PubMedGoogle Scholar
  • 3 Rodgers J, Ashton CH, Gilvarry E et al. Liquid ecstasy: a new kid on the dance floor. Br J Psychiatry 2004; 184: 104-106
    CrossrefPubMedGoogle Scholar
  • 4 Schwartz RH, Milteer R, LeBeau MA. Drug-facilitated sexual assault (“date rape”). South Med J 2000; 93: 558-561
    CrossrefPubMedGoogle Scholar
  • 5 Madea B, Musshoff F. K.-o.-Mittel: Häufigkeit, Wirkungsweise, Beweismittelsicherung. Dtsch Arztebl 2009; 106: 341-347
    PubMedGoogle Scholar
  • 6 Schütz H, Jansen M, Verhoff M. Vom Alkohol zum Liquid Ecstasy (GHB) – ein Überblick über alte und moderne K.-o.-Mittel – Teil 3: Gamma-Hydroxybuttersäure (GHB, “Liquid Ecstasy”). Arch Kriminol 2011; 228: 151-159
    PubMedGoogle Scholar
  • 7 Zvosec DL, Smith SW, McCutcheon JR et al. Adverse events, including death, associated with the use of 1,4-butanediol. N Engl J Med 2001; 344: 87-94
    CrossrefPubMedGoogle Scholar
  • 8 Bessman SP, Fishbein WN. Gamma-Hydroxybutyrate, a Normal Brain Metabolite. Nature 1963; 200: 1207-1208
    CrossrefPubMedGoogle Scholar
  • 9 Snead 3rd OC. Evidence for a G protein-coupled gamma-hydroxybutyric acid receptor. J Neurochem 2000; 75: 1986-1996
    PubMedGoogle Scholar
  • 10 Schep LJ, Knudsen K, Slaughter RJ et al. The clinical toxicology of gamma-hydroxybutyrate, gamma-butyrolactone and 1,4-butanediol. Clin Toxicol (Phila) 2012; 50: 458-470
    CrossrefPubMedGoogle Scholar
  • 11 Cammalleri M, Brancucci A, Berton F et al. Gamma-hydroxybutyrate reduces GABA(A)-mediated inhibitory postsynaptic potentials in the CA1 region of hippocampus. Neuropsychopharmacology 2002; 27: 960-969
    CrossrefPubMedGoogle Scholar
  • 12 Snead 3rd OC, Gibson KM. Gamma-hydroxybutyric acid. N Engl J Med 2005; 352: 2721-2732
    CrossrefPubMedGoogle Scholar
  • 13 Snead 3rd OC, Liu CC. Gamma-hydroxybutyric acid binding sites in rat and human brain synaptosomal membranes. Biochem Pharmacol 1984; 33: 2587-2590
    CrossrefPubMedGoogle Scholar
  • 14 Snead 3rd OC. Relation of the [3H] gamma-hydroxybutyric acid (GHB) binding site to the gamma-aminobutyric acidB (GABAB) receptor in rat brain. Biochem Pharmacol 1996; 52: 1235-1243
    CrossrefPubMedGoogle Scholar
  • 15 Snead 3rd OC. Presynaptic GABAB-and gamma-hydroxybutyric acid-mediated mechanisms in generalized absence seizures. Neuropharmacology 1996; 35: 359-367
    CrossrefPubMedGoogle Scholar
  • 16 Trendelenburg G, Ströhle A. Gamma-Hydroxybuttersäure – Neurotransmitter, Medikament und Droge. Nervenarzt 2005; 76: 832, 834-838
    PubMedGoogle Scholar
  • 17 Galldiks N, Kadow I, Bechdolf A et al. Symptomvielfalt nach Konsum der Droge Gamma- Hydroxybuttersäure (GHB). Fortschr Neurol Psychiatr 2011; 79: 21-25
    Article in Thieme ConnectPubMedGoogle Scholar
  • 18 Miro O, Nogue S, Espinosa G et al. Trends in illicit drug emergencies: the emerging role of gamma-hydroxybutyrate. J Toxicol Clin Toxicol 2002; 40: 129-135
    CrossrefPubMedGoogle Scholar
  • 19 Galicia M, Nogue S, Miro O. Liquid ecstasy intoxication: clinical features of 505 consecutive emergency department patients. Emerg Med J 2011; 28: 462-466
    CrossrefPubMedGoogle Scholar
  • 20 LoVecchio F, Curry SC, Bagnasco T. Butyrolactone-induced central nervous system depression after ingestion of RenewTrient, a “dietary supplement”. N Engl J Med 1998; 339: 847-848
    PubMedGoogle Scholar
  • 21 Chin RL, Sporer KA, Cullison B et al. Clinical course of gamma-hydroxybutyrate overdose. Ann Emerg Med 1998; 31: 716-722
    CrossrefPubMedGoogle Scholar
  • 22 Smith SW, Topliff AR, Danigelis M et al. Adverse Events Associated with Ingestion of Gamma-Butyrolactone Minnesota, New Mexico, and Texas, 1998–1999. MMWR Morb Mortal Wkly Rep 1999; 48: 137-140
    PubMedGoogle Scholar
  • 23 Tarabar AF, Nelson LS. The gamma-hydroxybutyrate withdrawal syndrome. Toxicol Rev 2004; 23: 45-49
    CrossrefPubMedGoogle Scholar
  • 24 McDonough M, Kennedy N, Glasper A et al. Clinical features and management of gamma-hydroxybutyrate (GHB) withdrawal: a review. Drug Alcohol Depend 2004; 75: 3-9
    CrossrefPubMedGoogle Scholar
  • 25 European-Monitoring-Centre-for-Drugs-and-Drug-Addiction-(EMCDDA). GHB and its precursor GBL: an emerging trend case study. Lisbon: European Monitoring Centre for Drugs and Drug Addiction; 2008
    PubMedGoogle Scholar
  • 26 Rath M. GHB/GBL (“Liquid Ecstasy”). In: Batra A, Bilke-Hentsch O, (eds) Praxisbuch Sucht. Stuttgart: Thieme; 2012: 197-202
    Google Scholar
  • 27 Heinz TW. Liquid Ecstasy – die neue Partydroge. Dtsch Arztebl 1998; 95: A-3119
    PubMedGoogle Scholar
  • 28 Knudsen K, Greter J, Verdicchio M et al. GHB, GBL and butanediol poisonings – a serious problem in Western Sweden. Lakartidningen 2005; 102: 3294-3296, 3299
    PubMedGoogle Scholar
  • 29 Liechti ME, Kunz I, Kupferschmidt H. Acute medical problems due to Ecstasy use. Case-series of emergency department visits. Swiss Med Wkly 2005; 135: 652-657
    PubMedGoogle Scholar
  • 30 Liechti ME, Kupferschmidt H. Gamma-hydroxybutyrate (GHB) and gamma-butyrolactone (GBL): analysis of overdose cases reported to the Swiss Toxicological Information Centre. Swiss Med Wkly 2004; 134: 534-537
    PubMedGoogle Scholar
  • 31 Anderson IB, Kim SY, Dyer JE et al. Trends in gamma-hydroxybutyrate (GHB) and related drug intoxication: 1999 to 2003. Ann Emerg Med 2006; 47: 177-183
    CrossrefPubMedGoogle Scholar
  • 32 Lange-Asschenfeldt C, Muller MJ, Szegedi A et al. Symptom-triggered versus standard chlormethiazole treatment of inpatient alcohol withdrawal: clinical implications from a chart analysis. Eur Addict Res 2003; 9: 1-7
    CrossrefPubMedGoogle Scholar
  • 33 Zvosec DL, Smith SW, Litonjua R et al. Physostigmine for gamma-hydroxybutyrate coma: inefficacy, adverse events, and review. Clin Toxicol 2007; 45: 261-265
    CrossrefPubMedGoogle Scholar
  • 34 Craig K, Gomez HF, McManus JL et al. Severe gamma-hydroxybutyrate withdrawal: a case report and literature review. J Emerg Med 2000; 18: 65-70
    CrossrefPubMedGoogle Scholar
  • 35 Sivilotti ML, Burns MJ, Aaron CK et al. Pentobarbital for severe gamma-butyrolactone withdrawal. Ann Emerg Med 2001; 38: 660-665
    CrossrefPubMedGoogle Scholar
  • 36 Schneir AB, Ly BT, Clark RF. A case of withdrawal from the GHB precursors gamma-butyrolactone and 1,4-butanediol. J Emerg Med 2001; 21: 31-33
    CrossrefPubMedGoogle Scholar
  • 37 LeBeau M, Andollo W, Hearn WL et al. Recommendations for toxicological investigations of drug-facilitated sexual assaults. J Forensic Sci 1999; 44: 227-230
    PubMedGoogle Scholar
  • 38 Elliott SP. Gamma hydroxybutyric acid (GHB) concentrations in humans and factors affecting endogenous production. Forensic Sci Int 2003; 133: 9-16
    CrossrefPubMedGoogle Scholar
  • 39 Erdmann F, Zandt D, Auch J et al. Untersuchungen zum Grenzwert zwischen endogener und exogener Gamma-Hydroxybuttersäure (GHB/liquid ecstasy. Arch Kriminol 2006; 217: 129-136
    PubMedGoogle Scholar
  • 40 Crookes CE, Faulds MC, Forrest AR et al. A reference range for endogenous gamma-hydroxybutyrate in urine by gas chromatography-mass spectrometry. J Anal Toxicol 2004; 28: 644-649
    CrossrefPubMedGoogle Scholar
  • 41 Hagenbuch F. GHB/GBL – der neue Kick?. Merkblatt der Landesärztekammer Ärzteblatt Baden-Württemberg 2011; 2: 93-95
    PubMedGoogle Scholar